---
title: Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell
  lymphoma
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009485/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: Despite the approval of several new treatments for patients with B-cell
  lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL)
  and Follicular lymphoma (FLs) are the two most common B-cell lymphoma subtypes,
  accounting for approximately 50% of all cases. EZH2 heterozygous gain-of-function
  somatic driver mutations are frequently found in Germinal Center B cell (GCB) DLBCLs
  and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed
  or refractory ...
disable_comments: true
---
Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FLs) are the two most common B-cell lymphoma subtypes, accounting for approximately 50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in Germinal Center B cell (GCB) DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory ...